Pelthos Therapeutics Added to Three Russell Indexes, Boosting Visibility to $12.2 Trillion
PTHS•Pelthos Therapeutics was added to the Russell 3000E Growth Benchmark, Russell Microcap and Russell Microcap Growth indexes effective June 29 during the June 2026 Russell US indexes reconstitution. Inclusion provides exposure to managers overseeing about $12.2 trillion in assets and underscores Pelthos’ progress expanding its commercial-stage biopharmaceutical portfolio.
1. Index Inclusion Details
Pelthos Therapeutics was added to the Russell 3000E Growth Benchmark, Russell Microcap and Russell Microcap Growth indexes effective June 29, 2026 as part of the semiannual reconstitution of up to 4,000 largest US stocks by April 30 market capitalization.
2. Exposure to Institutional Investors
Inclusion in these benchmarks positions Pelthos within strategies managing roughly $12.2 trillion in assets, potentially increasing institutional demand, index-driven inflows and trading volume in its shares.
3. Commercial and Strategic Milestones
Over the past year, Pelthos expanded its cutaneous infectious disease portfolio with ZELSUVMI, XEPI and XEGLYZE and strengthened its commercial organization to support its growth as a commercial-stage biopharmaceutical company.
